Initial Statement of Beneficial Ownership (3)
21 December 2021 - 10:01AM
Edgar (US Regulatory)
FORM 3
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0104
Estimated average burden
hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
|
1. Name and Address of Reporting Person
*
Schneyer Mark C. |
2. Date of Event Requiring Statement (MM/DD/YYYY)
12/9/2021
|
3. Issuer Name and Ticker or Trading Symbol
ACADIA PHARMACEUTICALS INC [ACAD]
|
|
(Last)
(First)
(Middle)
C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400 |
4. Relationship of Reporting Person(s) to Issuer (Check all applicable)
_____ Director _____ 10% Owner
___X___ Officer (give title below) _____ Other (specify below)
Chief Financial Officer / |
|
(Street)
SAN DIEGO, CA 92130
(City)
(State)
(Zip)
| 5. If Amendment, Date Original Filed(MM/DD/YYYY)
| 6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Beneficially Owned
|
1.Title of Security
(Instr. 4) | 2. Amount of Securities Beneficially Owned
(Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5) | 4. Nature of Indirect Beneficial Ownership
(Instr. 5) |
| Common Stock | 1303 | D | |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security
(Instr. 4) | 2. Date Exercisable and Expiration Date
(MM/DD/YYYY) | 3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4) | 4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5) | 6. Nature of Indirect Beneficial Ownership
(Instr. 5) |
| Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
| Employee Stock Option (Right to Buy) | (1) | 6/7/2030 | Common Stock | 41066 | $46.81 | D | |
| Employee Stock Option (Right to Buy) | (2) | 2/22/2031 | Common Stock | 19927 | $49.74 | D | |
| Restricted Stock Units | (3) | (3) | Common Stock | 5679 | (4) | D | |
| Restricted Stock Units | (5) | (5) | Common Stock | 5411 | (4) | D | |
| Restricted Stock Units | (6) | (6) | Common Stock | 39651 | (4) | D | |
| Restricted Stock Units | (7) | (7) | Common Stock | 39651 | (4) | D | |
| Explanation of Responses: |
| (1) | 25% of the shares subject to the Stock Option vested and became exercisable on June 8, 2021, and the remaining shares vest and become exercisable in 36 equal monthly installments thereafter. |
| (2) | 25% of the shares subject to the Stock Option vest and become exercisable on February 23, 2022, and the remaining shares vest and become exercisable in 36 equal monthly installments thereafter. |
| (3) | One-third of the shares subject to the restricted stock units vest on each of June 8, 2022, June 8, 2023 and June 8, 2024. |
| (4) | Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. |
| (5) | The restricted stock units vest in four equal annual installments beginning February 23, 2022. |
| (6) | The restricted stock units vest as follows: 37.5% of the shares vest 18 months from the grant date; 12.5% of the shares vest on the second anniversary of the grant date; and 25% of the shares vest on each of the third and fourth anniversaries of the grant date. |
| (7) | The restricted stock units vest as follows: 37.5% of the shares vest 18 months from the grant date; 12.5% of the shares vest on the second anniversary of the grant date; and 25% of the shares vest on each of the third and fourth anniversaries of the grant date. In addition, these restricted stock units may vest earlier upon the Issuer's common stock achieving a specified price per share over a specified trading period. |
Reporting Owners
|
| Reporting Owner Name / Address | Relationships |
| Director | 10% Owner | Officer | Other |
Schneyer Mark C.
C/O ACADIA PHARMACEUTICALS INC.
12830 EL CAMINO REAL, SUITE 400
SAN DIEGO, CA 92130 |
|
| Chief Financial Officer |
|
Signatures
|
| /s/ Austin D. Kim, Attorney-in-Fact | | 12/20/2021 |
| **Signature of Reporting Person | Date |
Acadia Pharmaceuticals (NASDAQ:ACAD)
Historical Stock Chart
From Mar 2024 to Apr 2024
Acadia Pharmaceuticals (NASDAQ:ACAD)
Historical Stock Chart
From Apr 2023 to Apr 2024
